Win for ResMed in patent war with Fisher & Paykel
The Munich District Court in Germany has found that sleep masks produced by Fisher & Paykel Healthcare infringe a European patent owned by ResMed.
Teva asks FTC to reopen Actavis and Watson merger decision
The US Federal Trade Commission yesterday said that Teva Pharmaceuticals has asked the commission to reopen and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.
United Therapeutics signs 3D bioprinting technology deal
Maryland-based United Therapeutics has inked a licence, development and commercialisation agreement with CollPlant, an Israeli biotech company, for 3D bioprinted lung transplants.
Federal Circuit refuses tribal immunity rehearing
In a blow to Allergan and the Saint Regis Mohawk Tribe, the US Court of Appeals for the Federal Circuit yesterday refused to reconsider an earlier decision that rejected use of tribal sovereign immunity in inter partes reviews.
Novartis to acquire radiopharma treatment developer
Novartis is planning to acquire Endocyte, an Indiana-based biotech, to accelerate its development of radiopharmaceuticals.
AbbVie enters Humira licensing deal with Fresenius Kabi
AbbVie has announced that it has entered into a licensing deal with Germany-based pharmaceutical company Fresenius Kabi.
Amgen injects £50m in UK gene-sequencing company
Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
EFPIA warns that SPC waiver will weaken EU IP framework
The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
US agencies to bolster cybersecurity of medical devices
The US Food and Drug Administration has announced that it has partnered with the US Department of Homeland Security as part of the FDA’s aim to strengthen cybersecurity in healthcare.
FDA lifts hold on first human CRISPR trial
The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
